Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy

Detalhes bibliográficos
Autor(a) principal: Arruda,Raissa M
Data de Publicação: 2021
Outros Autores: Batista,Andrea D, Filgueira,Norma A, Moura,Izolda F, Sette,Luis H, Lopes,Edmundo P
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Jornal Brasileiro de Nefrologia
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000100117
Resumo: Abstract In addition to liver disease, the hepatitis C virus (HCV) has been associated with autoimmune phenomena, such as mixed cryoglobulin and glomerulonephritis (GN). Until recently, both chronic hepatitis and HCV extra-hepatic manifestations were treated with peg-interferon plus ribavirin, however these drugs presented low efficacy and induced severe side effects. Nowadays, the HCV chronic hepatitis has been treated with direct acting antivirals (DAA), but studies on the DAA therapy for HCV-associated glomerulonephritis are scarce. Here, we describe two cases of HCV-associated glomerulonephritis that were treated with DAAs. In these two cases, previously experienced to peg-interferon plus ribavirin, the sofosbuvir plus simeprevir therapy was effective, without significant side effects, and interrupted the evolution of at least 20 years of both hepatic and renal diseases. These cases join the seven previously described cases that were treated with this DAAs association.
id SBN-1_1d9e640d44f78ee32eafab233e6e7715
oai_identifier_str oai:scielo:S0101-28002021000100117
network_acronym_str SBN-1
network_name_str Jornal Brasileiro de Nefrologia
repository_id_str
spelling Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapyHepacivirusGlomerulonephritisSofosbuvirSimeprevirCryoglobulinemiaAbstract In addition to liver disease, the hepatitis C virus (HCV) has been associated with autoimmune phenomena, such as mixed cryoglobulin and glomerulonephritis (GN). Until recently, both chronic hepatitis and HCV extra-hepatic manifestations were treated with peg-interferon plus ribavirin, however these drugs presented low efficacy and induced severe side effects. Nowadays, the HCV chronic hepatitis has been treated with direct acting antivirals (DAA), but studies on the DAA therapy for HCV-associated glomerulonephritis are scarce. Here, we describe two cases of HCV-associated glomerulonephritis that were treated with DAAs. In these two cases, previously experienced to peg-interferon plus ribavirin, the sofosbuvir plus simeprevir therapy was effective, without significant side effects, and interrupted the evolution of at least 20 years of both hepatic and renal diseases. These cases join the seven previously described cases that were treated with this DAAs association.Sociedade Brasileira de Nefrologia2021-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000100117Brazilian Journal of Nephrology v.43 n.1 2021reponame:Jornal Brasileiro de Nefrologiainstname:Sociedade Brasileira de Nefrologia (SBN)instacron:SBN10.1590/2175-8239-jbn-2019-0165info:eu-repo/semantics/openAccessArruda,Raissa MBatista,Andrea DFilgueira,Norma AMoura,Izolda FSette,Luis HLopes,Edmundo Peng2021-05-10T00:00:00Zoai:scielo:S0101-28002021000100117Revistahttp://www.bjn.org.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||jbn@sbn.org.br2175-82390101-2800opendoar:2021-05-10T00:00Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN)false
dc.title.none.fl_str_mv Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy
title Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy
spellingShingle Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy
Arruda,Raissa M
Hepacivirus
Glomerulonephritis
Sofosbuvir
Simeprevir
Cryoglobulinemia
title_short Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy
title_full Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy
title_fullStr Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy
title_full_unstemmed Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy
title_sort Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy
author Arruda,Raissa M
author_facet Arruda,Raissa M
Batista,Andrea D
Filgueira,Norma A
Moura,Izolda F
Sette,Luis H
Lopes,Edmundo P
author_role author
author2 Batista,Andrea D
Filgueira,Norma A
Moura,Izolda F
Sette,Luis H
Lopes,Edmundo P
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Arruda,Raissa M
Batista,Andrea D
Filgueira,Norma A
Moura,Izolda F
Sette,Luis H
Lopes,Edmundo P
dc.subject.por.fl_str_mv Hepacivirus
Glomerulonephritis
Sofosbuvir
Simeprevir
Cryoglobulinemia
topic Hepacivirus
Glomerulonephritis
Sofosbuvir
Simeprevir
Cryoglobulinemia
description Abstract In addition to liver disease, the hepatitis C virus (HCV) has been associated with autoimmune phenomena, such as mixed cryoglobulin and glomerulonephritis (GN). Until recently, both chronic hepatitis and HCV extra-hepatic manifestations were treated with peg-interferon plus ribavirin, however these drugs presented low efficacy and induced severe side effects. Nowadays, the HCV chronic hepatitis has been treated with direct acting antivirals (DAA), but studies on the DAA therapy for HCV-associated glomerulonephritis are scarce. Here, we describe two cases of HCV-associated glomerulonephritis that were treated with DAAs. In these two cases, previously experienced to peg-interferon plus ribavirin, the sofosbuvir plus simeprevir therapy was effective, without significant side effects, and interrupted the evolution of at least 20 years of both hepatic and renal diseases. These cases join the seven previously described cases that were treated with this DAAs association.
publishDate 2021
dc.date.none.fl_str_mv 2021-03-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000100117
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000100117
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/2175-8239-jbn-2019-0165
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Nefrologia
publisher.none.fl_str_mv Sociedade Brasileira de Nefrologia
dc.source.none.fl_str_mv Brazilian Journal of Nephrology v.43 n.1 2021
reponame:Jornal Brasileiro de Nefrologia
instname:Sociedade Brasileira de Nefrologia (SBN)
instacron:SBN
instname_str Sociedade Brasileira de Nefrologia (SBN)
instacron_str SBN
institution SBN
reponame_str Jornal Brasileiro de Nefrologia
collection Jornal Brasileiro de Nefrologia
repository.name.fl_str_mv Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN)
repository.mail.fl_str_mv ||jbn@sbn.org.br
_version_ 1752122066532827136

Registros relacionados